INMD Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 23.47% compared to InMode Ltd.'s net margin of -12425.36%. InMode Ltd.'s return on equity of 22.38% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 17.16%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 414.97%. Given that Perspective Therapeutics, Inc. has higher upside potential than InMode Ltd., analysts believe Perspective Therapeutics, Inc. is more attractive than InMode Ltd..

InMode Ltd. has a beta of 2.144, which suggesting that the stock is 114.37% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $93.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. InMode Ltd.'s net income of $21.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, InMode Ltd.'s price-to-earnings ratio is 6.63x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.65x versus 162.05x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nasus Pharma has a net margin of 23.47% compared to InMode Ltd.'s net margin of --. InMode Ltd.'s return on equity of 22.38% beat Nasus Pharma's return on equity of --.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 17.16%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that InMode Ltd. has higher upside potential than Nasus Pharma, analysts believe InMode Ltd. is more attractive than Nasus Pharma.

InMode Ltd. has a beta of 2.144, which suggesting that the stock is 114.37% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $93.2M, which are larger than Nasus Pharma quarterly revenues of --. InMode Ltd.'s net income of $21.9M is higher than Nasus Pharma's net income of --. Notably, InMode Ltd.'s price-to-earnings ratio is 6.63x while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.65x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

BiomX, Inc. has a net margin of 23.47% compared to InMode Ltd.'s net margin of --. InMode Ltd.'s return on equity of 22.38% beat BiomX, Inc.'s return on equity of -160.84%.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 17.16%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8264.78%. Given that BiomX, Inc. has higher upside potential than InMode Ltd., analysts believe BiomX, Inc. is more attractive than InMode Ltd..

InMode Ltd. has a beta of 2.144, which suggesting that the stock is 114.37% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $93.2M, which are larger than BiomX, Inc. quarterly revenues of --. InMode Ltd.'s net income of $21.9M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, InMode Ltd.'s price-to-earnings ratio is 6.63x while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.65x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 23.47% compared to InMode Ltd.'s net margin of 3.93%. InMode Ltd.'s return on equity of 22.38% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 17.16%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 145.78%. Given that Xtant Medical Holdings, Inc. has higher upside potential than InMode Ltd., analysts believe Xtant Medical Holdings, Inc. is more attractive than InMode Ltd..

InMode Ltd. has a beta of 2.144, which suggesting that the stock is 114.37% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $93.2M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. InMode Ltd.'s net income of $21.9M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, InMode Ltd.'s price-to-earnings ratio is 6.63x while Xtant Medical Holdings, Inc.'s PE ratio is 59.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.65x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.